Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
Status:
Terminated
Trial end date:
2017-09-26
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of
OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from
cisplatin chemotherapy regimens in the treatment of cancer.